2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

By afschroeder • August 5, 2025

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2025 Aug 4:ciaf424. doi: 10.1093/cid/ciaf424. Epub ahead of print. PMID: 40757658.

Tags: abatacept, covid-19, Harbor UCLA, Infectious Diseases, infliximab, pemivibart, Publications, vilobelimab

In Silico Design of a Multiepitope Vaccine Against Intestinal Pathogenic Escherichia coli Based on the 2011 German O104:H4 Outbreak Strain Using Reverse Vaccinology and an Immunoinformatic Approach

Youssef EG, Elnesr K, Hanora A. In Silico Design of a Multiepitope Vaccine Against Intestinal Pathogenic Escherichia coli Based on the 2011 German O104:H4 Outbreak Strain Using[...]

Effect of High Altitude on Small Pulmonary Vein and Artery Volume in the COPDGene Cohort: Towards Better Understanding of Lung Physiology and Pulmonary Disease

Kwee AKAL, Pompe E, Gallardo Estrella L, Charbonnier JP, Humphries SM, Tiddens HAWM, Crapo JD, Casaburi R, de Jong PA, Lynch DA, Mohamed Hoesein FAA.[...]

The Association of Niacin Use with Kidney Outcomes and Mortality

Takahashi R, Bui TA, Elali I, Tran D, Sumida K, Thomas F, Dukkipati R, Shah A, Rhee CM, Kovesdy CP, Kalantar-Zadeh K, Takahashi R. The[...]